Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esopha

Study title: 
Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esopha
Long title: 
Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esophageal squamous cell carcinoma or bladder carcinoma
Date receipt dossier: 
26 Mar 1998
Pharmaceutical study code: 
MEL01198
Company / Sponsor: 
Pasteur Mérieux Connaught
Phase: 
I
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Malignant melanoma, Non-Small Cell Lung Cancer, Squamous cell carcinoma of the Head and Neck, Bladder transitional cell carcinoma
Therapeutic approach: 
Immunotherapy
Genetic modification: 
HLA-A1 restricted CTL epitope of MAGE-1 and MAGE-3 genes
Method of transfer of nucleic acid of interest: 
Canarypox Virus (ALVAC)
Administered biological material: 
Recombinant Canarypox Virus
Route of administration: 
Subcutaneous
Locations in Belgium: 
Cliniques Universitaires St-Luc, Brussels
Type of procedure: 
Contained use only
Current status: 
Authorized